These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28974123)

  • 1. Bill C-30: who wins and who loses in Canada's pharmaceutical patent battles?
    Hollis A
    Expert Opin Ther Pat; 2018 Jan; 28(1):1-3. PubMed ID: 28974123
    [No Abstract]   [Full Text] [Related]  

  • 2. Mixed WTO ruling on generic drug development.
    Elliott R
    Can HIV AIDS Policy Law Newsl; 2000; 5(2-3):38-42, 40-4. PubMed ID: 11833195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canada ordered to implement WTO ruling against "stockpiling" of generic drugs.
    Elliott R
    Can HIV AIDS Policy Law Rev; 2000; 5(4):27. PubMed ID: 11833161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canada's Patented Medicines (Notice of Compliance) Proceedings and Intellectual Property.
    Bian H; McCourt C
    Cold Spring Harb Perspect Med; 2015 Jan; 5(6):. PubMed ID: 25573772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canada to change patent law to allow export of cheap drugs.
    Kondro W
    Lancet; 2003 Oct; 362(9392):1290. PubMed ID: 14577437
    [No Abstract]   [Full Text] [Related]  

  • 6. Long way down--pharmaceutical companies fear falling off 'patent cliff'.
    Sklan A
    Pharm Pat Anal; 2012 Jul; 1(3):240. PubMed ID: 24386667
    [No Abstract]   [Full Text] [Related]  

  • 7. The Eleventh Circuit holds that agreements in which pharmaceutical companies pay generic companies not to compete may be valid.
    Garrigues A
    J Law Med Ethics; 2004; 32(1):181-4. PubMed ID: 15152443
    [No Abstract]   [Full Text] [Related]  

  • 8. Canada wins legal battle to set patent rules.
    Webster P
    CMAJ; 2017 Apr; 189(15):E578. PubMed ID: 28420686
    [No Abstract]   [Full Text] [Related]  

  • 9. Reforming Canada's Access to Medicines Regime.
    Esmail LC
    CMAJ; 2007 Jul; 177(3):270. PubMed ID: 17664454
    [No Abstract]   [Full Text] [Related]  

  • 10. Reforming Canada's Access to Medicines Regime.
    Elliott R
    CMAJ; 2007 Jul; 177(3):270-1. PubMed ID: 17664453
    [No Abstract]   [Full Text] [Related]  

  • 11. Canada's patented medicine notice of compliance regulations: balancing the scales or tipping them?
    Lexchin J
    BMC Health Serv Res; 2011 Mar; 11():64. PubMed ID: 21435247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRIPS from Doha to Cancún ... to Ottawa: global developments in access to treatment and Canada's Bill C-56.
    Elliott R
    Can HIV AIDS Policy Law Rev; 2003 Dec; 8(3):1, 7-18. PubMed ID: 15104062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patent watch.
    Harrison C
    Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274462
    [No Abstract]   [Full Text] [Related]  

  • 14. Preliminary injunctions in generic and branded patent litigation.
    Cohen S; England P
    Expert Opin Ther Pat; 2013 Sep; 23(9):1083-6. PubMed ID: 23855903
    [No Abstract]   [Full Text] [Related]  

  • 15. Indian biogenerics industry emerges.
    Jayaraman KS
    Nat Biotechnol; 2003 Oct; 21(10):1115-6. PubMed ID: 14520378
    [No Abstract]   [Full Text] [Related]  

  • 16. Right idea, wrong result--Canada's access to medicines regime.
    Goodwin PE
    Am J Law Med; 2008; 34(4):567-84. PubMed ID: 19216248
    [No Abstract]   [Full Text] [Related]  

  • 17. Teva Pharmaceuticals v. Sandoz: availability of generic glatiramer acetate and the impact to patent litigation claim construction.
    Fogel LE; Ray CJ
    Expert Opin Ther Pat; 2015 Jan; 25(1):1-4. PubMed ID: 25363310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. India's new patent bill threatens generic industry.
    Ahmad K
    Lancet Infect Dis; 2005 May; 5(5):265. PubMed ID: 15889471
    [No Abstract]   [Full Text] [Related]  

  • 19. Patent watch: the patent cliff steepens.
    Harrison C
    Nat Rev Drug Discov; 2011 Jan; 10(1):12-3. PubMed ID: 21193859
    [No Abstract]   [Full Text] [Related]  

  • 20. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV
    Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.